CONTRAD SWISS
Aleksei Nikolaev, MD, MBA, is a seasoned medical marketing professional with extensive experience in driving marketing strategies within the healthcare and consumer goods sectors. Currently serving as the Global Medical Marketing Manager for Aesthetics at CONTRAD SWISS, Aleksei oversees the introduction of new aesthetic products in various markets and supports existing partners. Previous roles include Global Medical Marketing Head at Galderma, where Aleksei led initiatives to enhance brand recommendations among healthcare professionals and supported growth in a competitive skincare market. Aleksei's career includes significant achievements at Danone, Pfizer, and Johnson & Johnson, with a strong foundation in product management and strategic marketing. Aleksei holds an MBA from IESE Business School and a Doctor of Medicine from First Moscow State Medical University named after I.M. Sechenov.
This person is not in any teams
CONTRAD SWISS
CONTRAD SWISS is a dynamic Swiss-based pharmaceutical corporation revolutionizing the regenerative medicine landscape. Headquartered in Lugano, Contrad Swiss is the owner of proprietary SIGMOLECS® Technology which takes the current use of peptides as active ingredients a giant step forward. The company portfolio comprises medical devices and aesthetic products, positioned in the premium segment, delivering unparalleled value. SIGMOLECS® is a unique technology guiding cell behaviour for a wide range of treatments. It talks to cells in their own language, enabling more effective therapies. It is designed to work with various treatment methods, following the body's natural systems and also enhancing the penetration of other important molecules. This breakthrough technology, utilizing customized peptide sequences, is the driving force behind our specialized non-invasive product lines in Orthopaedics (500Line), Aesthetic Medicine (ACTV8 PRO), and in our targeted alleviating lotion (Egyfil), all supported by recently published peer-reviewed studies. The 500Line, powered by SIGMOLECS®, addresses unmet clinical needs in osteoarthritis and connective tissue pathology through non-invasive, rapid-acting formulations. Egyfil offers targeted relief for muscle & joint stiffness and discomfort. ACTV8 PRO is designed for regenerative aesthetic physicians. CONTRAD SWISS is signaling the future of regenerative medicine.